These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10707193)

  • 1. Use of apomorphine in Parkinson's disease.
    O'Sullivan JD; Lees AJ
    Hosp Med; 1999 Nov; 60(11):816-20. PubMed ID: 10707193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F
    Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine (Apokyn) for advanced Parkinson's Disease.
    Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
    Koller W; Stacy M
    Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.
    Borgemeester RW; Lees AJ; van Laar T
    Parkinsonism Relat Disord; 2016 Jun; 27():35-40. PubMed ID: 27132157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attempted suicide under high dose dopaminergic therapy including apomorphine.
    Struhal W; Guger M; Hödl S; Ung SC; Bach M; Ransmayr G
    Wien Klin Wochenschr; 2012 Jul; 124(13-14):461-3. PubMed ID: 22797806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous apomorphine infusion in advanced idiopathic Parkinson's disease and agranulocytosis: a case report.
    Condé S; Marques A; Derost P; Debilly B; Lauxerois M; Chanson E; Durif F
    Parkinsonism Relat Disord; 2020 Sep; 78():68-69. PubMed ID: 32739839
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.